SV Life Sciences — Full Portfolio
12 tracked investments · listed companies and verified rows first
American Well operates a digital healthcare platform that connects patients, physicians, and healthcare professionals to provide remote clinical services, earning revenue through arrangements with healthcare organizations and clients who use its technology to deliver telehealth and related services.
HealthtechBoston, US
Ido Schoenberg(Executive Officer, Director)inRoy Schoenberg(Executive Officer, Director)inJames Malone(Executive Officer)inBradford F. Gay(Executive Officer)Phyllis Gotlib(President, International)inMark Hirschhorn(Executive Vice President, Chief Financial Officer and Chief Operating Officer)in
Co-investorsHanaco Venture CapitalMartin VenturesSV Health Investors
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in
Co-investorsForesite CapitalGV (Google Ventures)Dementia Discovery FundDementia DiscoveryLightstone VenturesSV Health Investors+2 more
HealthtechSunnyvale, US
Thomas Afzal(Executive Officer, Director)
BoardPeter van der Velden(Director)inDan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)
Board seatDavid Milne· per SEC Form D · $1.6M raise · filed Nov 2016
Co-investorsHLM Venture PartnersLumira VenturesSV Health Investors
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.
AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)inTodd M. Pope(Executive Officer, Director)inJoseph P Slattery(Executive Officer)inJames J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)Jeffrey G. Spragens(Executive Officer, Director)
Board seatDavid B Milne· per SEC Form D · $950K raise · filed Sep 2017
Co-investorsAisling CapitalSV Health InvestorsQuaker BioVentures
BiotechIrvine, US
Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)
BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)
Co-investorsEvidity Health CapitalFlying L PartnersHEALTHCARE ROYALTY PARTNERSVersant Venture AIV HoldingsVersant Ventures
Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.
AI & Machine LearningBiotechDeep TechVermont, US
Co-investorsGrandBanks CapitalLaunchCapitalLux CapitalPremji InvestSV Health InvestorsMithril Capital Management+1 more
Repligen provides bioprocessing technologies—including process intensification, tangential flow filtration, chromatography, process analytics, and single-use fluid management—for upstream and downstream biopharmaceutical workflows.
BiotechHardwareMedical DevicesLebanon, US
Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)
Co-investorsOrbiMedSV Health InvestorsBorealis VenturesMithril Capital ManagementPolaris PartnersSands Capital Ventures
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSofinnova VenturesSV Health InvestorsClarus
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalJeito CapitalLongwood FundSR One Capital ManagementSV Health Investors+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.